ARC-7
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
- NCT04262856 ↗
- Completed
- Arcus Biosciences, Inc.
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on ARC-7 (domvanalimab plus zimberelimab; domvanalimab plus zimberelimab plus etrumadenant; zimberelimab in front-line PD-L1 positive non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ARC-7 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 posts on X | |
| 3 podcast episodes | |
| 1 YouTube video |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer; Lung Cancer
- Interventions
- Domvanalimab; Etrumadenant; Zimberelimab
- Arms
- Arm 1 (zimberelimab monotherapy) · Experimental
- Arm 2 (domvanalimab and zimberelimab combination therapy) · Experimental
- Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy) · Experimental
- Enrollment
- 151
- Primary outcomes
- Objective response rate (ORR)
- Progression-free survival (PFS)
- Sponsor
- Arcus Biosciences, Inc. with Gilead Sciences
- Start
- May 28, 2020
- Primary completion
- Jul 9, 2025
- Results posted
- No
- Registry record
- NCT04262856 · updated Jun 15, 2026